INB-100

Post-BMT infusion of donor-derived, EAGD cells has demonstrated manageable safety with no infusional toxicity or ≥G3 acute GvHD or extensive chronic GvHD. Durable relapse free survival at a maximum of >3 years in subjects with poor risk cytogenetics and adverse clinical risk factors combined with ongoing homeostatic reconstitution of increasing gd T cell effectors post-BMT suggests this therapy may be an effective measure in mitigating relapse after HaploBMT. NCT03533816

The preliminary results of this Phase 1 study of donor-derived, EAGD cells has demonstrated the therapy to have a robust safety profile, with no infusional toxicity, treatment associated SAEs, or grade 3-4 acute or extensive chronic GVHD. The absence of relapse suggest the possibility that this therapy will be an effective measure in mitigating relapse after HaploBMT.